SNMP, VERO and PRAX among mid-day movers

Stock Information for Evolve Transition Infrastructure LP representing Class B Limited Liability Company Interests

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evolve Transition Infrastructure LP representing Class B Limited Liability Company Interests

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Mesoblast Financial Results and Corporate Update Webcast
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.